Please assess the completion status of the following clinical trial:

Trial Title: Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed biliary tract carcinoma~  * Surgically unresectable disease~* Meets any of the following criteria for biliary cancers only:~  * Received ≤ 1 prior systemic anticancer therapy, including chemoembolization~ * Received prior cryotherapy, radiofrequency ablation, ethanol injection, transarterial chemoembolization, or photodynamic therapy AND meets the following criteria:~    * More than 6 weeks have elapsed since any of the prior therapy described above~   * Indicator lesion(s) must be outside the area of prior treatment OR must demonstrate clear evidence of disease progression if the only indicator lesion is inside the prior treatment area~   * Indicator lesion must have clearly distinct edges on CT scan~ * Prior radiotherapy with or without the use of a fluoropyrimidine as a radiosensitizer is allowed, provided more than 12 weeks have elapsed since treatment~* Fresh or paraffin-embedded tissue from tumor blocks must be available for review~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan~* No known brain metastases~* Life expectancy \> 12 weeks~* ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%~* ANC ≥ 1,500/μL~* Platelet count ≥ 75,000/μL~* Total bilirubin ≤ 2 times upper limit of normal(ULN)~* AST or ALT ≤ 3 times ULN~* Serum albumin ≥ 2.5 mg/dL~* INR ≤ 1.5 (not receiving anticoagulation therapy)~* Creatinine normal or creatinine clearance ≥ 60 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile women must use effective contraception during and for four weeks after the last dose of AZD6244~* Fertile men must use effective contraception during and for 16 weeks after the last dose of AZD6244~* No significant traumatic injury within the past 3 weeks~* No uncontrolled symptoms consistent with encephalopathy~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or its excipient, Captisol®~* No QTc interval \> 500 msecs or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., hypokalemia or family history of long QT interval syndrome), including NYHA class III-IV heart failure~* No other malignancy within the past 3 years, except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No refractory nausea and vomiting, chronic gastrointestinal disease (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption~* No uncontrolled concurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements~* No malignant hypertension within the past year~* No prior sorafenib or MEK inhibitors~* More than 4 weeks since prior chemotherapy, biologic therapy, or immunotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered to ≤ grade 1 adverse events~* No major surgery within the past 3 weeks~* No other concurrent investigational agents~* No concurrent requirement for medication that can prolong the QT interval~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent consumption of grapefruit or grapefruit juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy) (Type: EXPERIMENTAL): Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).